Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY PMDA Stops Increasing Review Staff, Current Review-Time Targets to Remain Unchanged: Chief Executive
January 16, 2017
-
REGULATORY Industry Speculating Tax Hike Will Delay Annual Revision Rollout to 2021
January 13, 2017
-
REGULATORY Chuikyo Industry, Doctor Reps in Discord over Scope of Price Review for Indication Expansions
January 12, 2017
-
BUSINESS Ariad Deal Is “Global Acquisition” Not Limited to US Market: Takeda CEO
January 11, 2017
-
REGULATORY Chuikyo to Kick Off Debates to Elaborate Pricing Revamp; 2 Industry Hearing Sessions Planned
January 11, 2017
-
BUSINESS Opdivo Gastric Cancer Filing Casts Cloud on Keytruda’s Sakigake Status
January 10, 2017
-
BUSINESS Takeda to Buy US Oncology Firm Ariad
January 10, 2017
-
REGULATORY MHLW to Regularly Compile Optimal Drug Use Guidelines from FY2017: Pharma Bureau Chief
January 6, 2017
-
REGULATORY From Regulatory Agency to Industry-Fostering Agency: Health Minister
January 5, 2017
-
REGULATORY Policymakers Rolling Up Their Sleeves to Embody Drug Pricing Overhaul
January 1, 2017
-
REGULATORY AMED Plans to Introduce Medical-Economic Viewpoints for Its R&D Support
December 28, 2016
-
BUSINESS 40 Billion Yen Sales for Oncology Business in FY2020 Achievable: Daiichi Sankyo
December 27, 2016
-
ORGANIZATION Novo’s Ole Moelskov Bech to Helm EFPIA Japan from January
December 26, 2016
-
BUSINESS Sumitomo Dainippon to Buy US Hematology Startup Tolero
December 22, 2016
-
BUSINESS Ono Slashes Opdivo Sales Outlook on 50% Price Cut
December 22, 2016
-
REGULATORY Quarterly Price Reviews for Indication-Added Drugs Likely to Get Underway in FY2017, Annual Scheme in FY2018: Officials
December 21, 2016
-
BUSINESS New Technologies to Cure Cancers, Help Reduce Medical Expenditure: Report
December 21, 2016
-
REGULATORY Four Ministers Map Out Basic Policy for Drug Pricing Revamp
December 21, 2016
-
REGULATORY Basic Policy for Drastic Reform of Drug Pricing System
December 20, 2016
-
BUSINESS Keytruda Gets NSCLC Nod Both in 1st-Line, 2nd-Line Settings
December 20, 2016
ページ
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…